Abiopharma

🔍 Hyzak Dwayne L. (Executive)

Company: Main Street Capital CORP (MAIN)

Report Date: 2026-06-15

Detailed Transactions and Holdings:

• Acquired 447 shares of Common Stock at $52.02 per share (Direct)
  Date: 2026-06-15 | Code: J | equity_swap_involved: 0 | shares_owned_after: 507,294.74 | transaction_form_type: 5 | Footnotes: F1
• Acquired 529 shares of Common Stock at $51.01 per share (Direct)
  Date: 2026-06-29 | Code: J | equity_swap_involved: 0 | shares_owned_after: 507,823.43 | transaction_form_type: 5 | Footnotes: F1
• Acquired 451 shares of Common Stock at $53.09 per share (Direct)
  Date: 2026-07-15 | Code: J | equity_swap_involved: 0 | shares_owned_after: 508,274.79 | transaction_form_type: 5 | Footnotes: F1

Footnotes:

• F1: The reporting person acquired these shares under a dividend reinvestment plan, pursuant to a dividend reinvestment transaction exempt from Section 16 under Rule 16a-11.